Skip to content
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Northwest Territories Becomes Fifth Jurisdiction in Canada to Implement Biosimilar Switching Initiative

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Government of the Northwest Territories that it will implement a “switching” or transitioning policy to expand the use of biosimilar medicines under its public drug programs.
Read more

Cessation of public coverage for Lovenox enoxaparin in Quebec

As of December 15, 2021, only biosimilars to Lovenox and Lovenox HP enoxaparin will be reimbursed by the Quebec public drug plan. Patients already being treated with Lovenox have until April 12, 2022, to switch to a biosimilar.

Read more

Cessation of public coverage for Forteo in Quebec

As of December 15, 2021, only biosimilars to Forteo teriparatide will be reimbursed by the Quebec public drug plan. Patients currently being treated with Forteo have until April 12, 2022 to switch to a biosimilar.

Read more